Back to top
more

AxoGen (AXGN)

(Delayed Data from NSDQ)

$14.69 USD

14.69
779,431

+0.40 (2.80%)

Updated Sep 17, 2024 04:00 PM ET

After-Market: $14.69 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Should You Continue to Retain MYGN Stock in Your Portfolio?

by Zacks Equity Research

Myriad Genetics is advancing with strategic priorities, and bringing new products and upgrades to the market, positively influencing investors' sentiment.

PEN Stock to Gain From CE Mark Approval for its CAVT Technologies

by Zacks Equity Research

Penumbra receives the CE Mark approval for Lightning Flash 2.0 and Lightning Bolt 7 in Europe.

IINN Stock Gains on Second US Patent Approval for VORTX System

by Zacks Equity Research

Inspira secures a second U.S. Patent approval for the VORTX orbiting blood oxygenation delivery system.

Here's Why You Should Add Inogen Stock to Your Portfolio Now

by Zacks Equity Research

Expanding product portfolio and high prospects for POC raise optimism for the INGN stock.

PAHC Stock Gains From Innovation, Market Expansion Goal

by Zacks Equity Research

Phibro Animal Health's nutritional product offerings, such as OmniGen-AF and Animate, are being increasingly used in the global dairy industry.

Can QGEN Stock Gain From the Expanded Bio-Manguinhos/Fiocruz Alliance?

by Zacks Equity Research

QIAGEN and Bio-Manguinhos/Fiocruz team up to enhance malaria and dengue detection in Brazil's national screening programs.

Owens & Minor Stock to Gain From New Collaboration With Google Cloud

by Zacks Equity Research

OMI announces partnership with Google Cloud to enhance existing QSight capabilities.

Should You Continue to Retain OMCL Stock in Your Portfolio Now?

by Zacks Equity Research

Omnicell is well-placed for growth in the upcoming quarters owing to its progress in achieving the Autonomous Pharmacy goal.

LH Stock Expected to Gain From the Ballad Health Acquisition Deal

by Zacks Equity Research

Labcorp has reached an agreement to purchase select outreach laboratory services from Ballad Health.

HSIC Stock Likely to Get a Boost From New Henry Schein One Launches

by Zacks Equity Research

Henry Schein's dental software arm unveils Dentrix Eligibility offerings to elevate the insurance verification process.

CRL Stock May Benefit From New Neuroscience Research Collaboration

by Zacks Equity Research

Charles River's new alliance with Insightec to advance therapeutic development using focused ultrasound in neuroscience.

Here's Why VCYT Stock Could be a Great Addition to Your Portfolio Now

by Zacks Equity Research

Veracyte looks poised to deliver robust performance owing to its progress with key drivers and the strength in its diagnostics tests.

AxoGen, Inc. (AXGN) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

AxoGen (AXGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

EW Stock Dips Following the Divestiture of Critical Care Wing

by Zacks Equity Research

Edwards completes the sale of its Critical Care operations and announces a $1 billion share repurchase program.

EW Stock to Benefit From Favorable RHEIA Trial Data on TAVI

by Zacks Equity Research

Edwards' first all-female TAVI Trial demonstrates favorable outcomes for women receiving Edwards valves.

What Makes AxoGen (AXGN) a Strong Momentum Stock: Buy Now?

by Zacks Equity Research

Does AxoGen (AXGN) have what it takes to be a top stock pick for momentum investors? Let's find out.

QIAGEN and AstraZeneca Expand Pact to Develop CDx in Chronic Diseases

by Zacks Equity Research

QGEN's expanded collaboration with AstraZeneca to focus on developing companion diagnostics beyond oncology.

Boston Scientific's ACURATE Prime Aortic Valve System Wins CE Mark

by Zacks Equity Research

BSX achieves CE Mark approval for the ACURATE Prime Aortic Valve System, its latest TAVR technology.

Wall Street Analysts See a 25.51% Upside in AxoGen (AXGN): Can the Stock Really Move This High?

by Zacks Equity Research

The mean of analysts' price targets for AxoGen (AXGN) points to a 25.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

AxoGen, Inc. (AXGN) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

AxoGen (AXGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

AxoGen (AXGN) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

AxoGen (AXGN) delivered earnings and revenue surprises of 200% and 10.74%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

AxoGen (AXGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

AxoGen (AXGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CVRx (CVRX) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

CVRx (CVRX) delivered earnings and revenue surprises of -27.45% and 0.28%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

What's in Store for DENTSPLY SIRONA (XRAY) in Q2 Earnings?

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) second-quarter results are likely to reflect growth in the Wellspect Healthcare business and Orthodontic segment amid foreign exchange headwinds.

Cencora (COR) to Report Q3 Earnings: Is a Beat in Store?

by Zacks Equity Research

Cencora's (COR) third-quarter fiscal 2024 results are likely to reflect solid performance in the U.S. Healthcare Solutions segment.